Objective: to determine the impact of Factor V-Leiden on the patency of peripheral vascular reconstructions. Design: prospective, open and consecutive study. Methods: a total of 775 patients, who were electively admitted between 1995 and 1997 to the vascular ward unit, were prospectively analysed for frequency of Factor V-Leiden mutation and patency of reconstruction (one month and one year). The patients were grouped into carotid, abdominal aortic aneurysm (AAA), renal artery, aortoiliac, infrainguinal, and venous categories according to procedures and anatomical sites. Post-reconstruction complications and associated risk factors were also analysed. Result: in infrainguinal patients Factor V-Leiden was seen in 16% of the patients compared with 10% in the controls. (Odds ratio 1.60, CI 0.91-2.81). Hypertension, pulmonary disease and smoking were more frequent in individuals without Factor V-Leiden. Analysing all 775 reconstructions, occlusions were more frequent at one month (14% vs 12%) (p= 0.02) in patients with Factor V-Leiden compared with patients without the mutation. Though this trend was also noted few patients having infrainguinal reconstructions, the difference was not significant (37% vs 22% (p=0.15) and 46% vs 27% (p=0.09) after 1 and 12 months, respectively). Conclusion: factor V mutation (Factor V-Leiden) was more frequent in patients having occluded vascular reconstructions. Further evaluation is needed.
Introduction
venous thrombosis, the role of Factor V-Leiden mutation as a risk factor for arterial thrombosis is unclear. The vitamin K-dependent plasma protein. Protein C,
The role of Factor V-Leiden in coronary bypass grafting occlusion has not been established. 15 Two when activated (Activated Protein C or APC) on endothelial cells by thrombin-thrombomodulin complex, studies of peripheral vascular reconstruction 16,17 suggested a lower patency in patients with low APC ratio. inhibits clotting selectively by degrading coagulation factors Va and VIIIa. [1] [2] [3] [4] [5] [6] Protein S, also a K vitamin-The aim of this prospective study was to determine the impact of Factor V-Leiden on the short-term post-dependent plasma protein, functions as a cofactor to APC.
operative thrombotic events (occlusions) in peripheral vascular reconstructions. Inherited APC resistance is now known to be due to (Arg506 to Gln) in the Factor V (Factor V-Leiden). [4] [5] [6] As a result of this mutation one of three APC cleavage sites is lost, which renders it unavailable as a cofactor Material and Method to APC [3] [4] [5] [6] resulting in the hypercoagulable state. Factor V-Leiden is found in 20-60% of analysed patients A total of 775 patients undergoing elective vascular with venous thromboembolism [7] [8] [9] [10] [11] and in a venous reconstructions between January 1995 and 1997 were thrombosis cohort. 12, 13 In Malmö the frequency of Facprospectively and consecutively included. Clinical tor V-Leiden is 7-11 in the general population, 7, 12 renal artery, aortoiliacal, infrainguinal, and venous before one month and 102 by one-year follow-up. Table 1 shows the rate of mortality and frequency of including open and endovascular procedures. This grouping is in line with the Eurovasc Report 1997. 20 Factor V-Leiden among the different groups. Table 2 compares the frequencies of associated risk factors. Operations at different anatomical sites were counted as separate operations. After a follow-up period of 12 Hypertension (OR 0.62; CI 0.39-0.97), pulmonary disease (OR 0.43; CI 0.21-0.88) and smoking (OR 0.60; CI months any procedure at the same anatomical sites was regarded as a new reconstruction and followed 0.36-0.99) were more frequent in patients without Factor V-Leiden mutation. Post-reconstruction com-for another 12 months. A patient was recorded as occluded only once, if occlusion occurred in one or plications ( Table 3 ) showed higher frequency of deep or graft infection and occlusion/thrombosis in the more reconstructions at the same anatomical site. This study does not intend to analyse the different index Factor V-Leiden mutation group. At one month there were few recorded occlusions for carotid, AAA, or procedures in each category separately.
Follow-up was carried out between February 1995 renal artery patients with or without Factor V-Leiden. A non-significant tendency for early occlusion in aorto-and December 1998. Patients were called for followup one month and one year after reconstructions. iliac individuals and patients who had infra-inguinal procedures with Factor V-Leiden was seen ( Table 4 ). During these follow-up periods the patients underwent clinical status evaluation, noninvasive ex-In the total series occlusion at one month and 1 year occurred significantly more often in patients with Fac-amination, and angiography if indicated. Function/ patency was recorded as patent-improved, patent-tor V-Leiden: 14% vs 7% and 22% vs 12%, respectively ( Table 4 ). At one year 148 patients did not undergo unchanged, patent but deteriorating, patent-dead, death as a result of other causes, occluded-improved, follow-up examinations for patency leaving us with 627 original patients of whom 12% (77/627) had Factor occluded-unchanged occluded-deteriorating, occludeddead. For secondary patency, patients were recorded V-Leiden. as secondary patency-improved, unimproved, unchanged or dead. To determine patency/occlusion a combination of clinical, haemodynamic and an-Discussion giographic factors were employed as indicated. All carotid patients underwent routinely neurologic and
The importance of APC resistance for venous thromduplex examination within two months after the probosis is established, [21] [22] [23] but for arterial thrombosis cedures. All patients undergoing vascular rethe findings are less certain. Several studies on APC construction were started on low molecular weight resistance and myocardial infarction have not conheparin before operation and until discharge. After firmed APC resistance as a risk factor. 14,24 Graft ocdischarge most patients continued with antiplatelet clusion after coronary artery bypass surgery has not therapy (low dose ASA normally 75-160 mg daily).
been found to be higher in APC-resistant patients than Associated risk factors and post-reconstructive comin those who are not. 15 Results from studies on stroke plications were also analysed and compared among and APC resistance with or without Factor V-Leiden the groups. Mortality was controlled by the Swedish gene analyses are still conflicting. 11,24-25 One study, National Death Registry.
evaluating the prevalence of APC resistance in patients with peripheral vascular disease and correlating the disorder to outcome after vascular surgery, suggests Statistical analysis APC resistance as relatively common in patients with peripheral vascular disease. 16 This study also suggests A comparison within the groups was done with a Yates APC resistance as a risk factor for failure of infracorrected Chi-square test. Significance was assumed inguinal bypass. In another study, Donaldson et al. 17 when a p-value of less than 0.05 was achieved. Odds suggested, although weakly, like Ouriel et al., 16 a higher ratio (OR) and 95% confidence interval (CI) were risk of occlusion in infrainguinal reconstructions, but calculated.
found that Factor V-Leiden mutation was not more prevalent in peripheral vascular surgical patients than in a control population. In contrast to their findings we have found, in this analysis and an earlier study, 26 
Results
an increased incidence of the Factor V-Leiden mutation in patients with infrainguinal, peripheral vascular dis-Twelve percent (93/775) of patients were heterozygotes for Factor V-Leiden (Table 1) . Thirty-six died ease. Fisher et al. 27 have recently in their studies also indicated a greater prevalence of APC resistance in patients undergoing peripheral arterial bypass grafting and a trend for APC resistance to be associated with graft failure.
The lower rate of hypertension, pulmonary disease and smoking in patients with Factor V-Leiden mutation must be interpreted cautiously. No other reports to our knowledge support such an associated pattern.
This prospective study was started to determine if there existed any differences in the rate of occlusion/ patency after peripheral vascular procedures in patients with Factor V-Leiden mutation. This study limits itself to divisions in peripheral vascular reconstructions to achieve its objectives without delving into the index procedures separately. We are aware of the fact that post-reconstruction occlusion is a complex process involving the type of reconstruction, the runoff situation, smoking habits, graft material etc. Likewise, other abnormalities of the anticoagulant system besides the Factor V-Leiden, such as hereditary deficiencies of protein C, S, antithrombin III, and the prothrombin G20210A mutation, could influence the postreconstructive occlusion rate. Twelve percent of our patients had Factor V mutation. In a control population age matched and from the same area inherited APC resistance is seen in 7-11%. 26 There is a trend of a higher prevalence of inherited APC resistance in peripheral vascular surgery patients as a whole with the exception of those with carotid and renal artery diseases. A higher prevalence of Factor V-Leiden was found in infrainguinal patients, 16%, and in venous patients, 21%. This is in agreement with our previous findings. 26 In this study, we noted a higher occlusion rate in the subgroup of infrainguinal procedures with Factor V mutations within the first month (p=0.09) and one year (p=0.05) after reconstruction. This finding is supported by other groups. 16, 17 The increased risk of occlusion noted in this study in the aortoiliac and venous groups is in line with other earlier studies, 8,10,12,23 but due to our small number of occluded reconstructions, this needs to be cautiously evaluated.
Presently, besides poor run-in and run-off, early graft occlusion (within 30 days) is most often considered to be the result of technical problems. Graft occlusion after one month but within one year after reconstruction has been judged to be a result of graft stenosis or intimal hyperplasia. APC resistance is now found in patients with venous thrombosis to be at least 10 times more common than any other inherited deficiencies of anticoagulant proteins. 7 In patients with inherited APC-resistance due to Factor V gene mutation, a two-fold risk for early occlusion in lower ex- In conclusion, we have in this study found a sig-11 Halbmayer WM, Haushofer A, Schö n R, Fischer M. The nificantly higher frequency of early occlusion of vasprevalence of poor anticoagulant response to activated protein C (APC-resistance) among patients suffering from stroke or cular procedures in patients with inherited APC venous thrombosis and among healthy subjects. Blood Coagul resistance due to Factor V mutation. Infrainguinal 
